Patent SG-11201906767X-A (SG)
Title: Estrogen receptor modulators
Inventor: SCOTT JAMES
IPC: A61K31/501
Filed: 2018-01-29
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 August 2018 (02.08.2018) Iiiiionoilloionliol OMMI 11100111001110#011 (10) International Publication Number WO 2018/138303 Al WIPO I PCT (51) International Patent Classification: CO7D 471/04 (2006.01) A61K 31/506 (2006.01) A61P 35/00 (2006.01) A61K 31/501 (2006.01) A61K 31/437 (2006.01) (21) International Application Number: PCT/EP2018/052040 (22) International Filing Date: 29 January 2018 (29.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/451,971 30 January 2017 (30.01.2017) US 62/523,695 22 June 2017 (22.06.2017) US 62/560,304 19 September 2017 (19.09.2017) US 62/592,485 30 November 2017 (30.11.2017) US (71) Applicant: ASTRAZENECA AB [SE/SE]; SE-151 85 Sodertalje (SE). (72) Inventors: SCOTT, James, Stewart; AstraZeneca Dar- win Building, Cambridge Science Park, Milton Road Cam- bridge CB4 OWG (GB). MOSS, Thomas, Andrew; As- traZeneca Darwin Building, Cambridge Science Park, Mil- ton Road Cambridgeshire CB4 OWG (GB). HUGHES, Samantha, Jayne; AstraZeneca Darwin Building, Cam- bridge Science Park, Milton Road, Cambridge Cam- bridgeshire CB4 OWG (GB). NISSINK, Johannes, Wil- helmus, Maria; AstraZeneca, Darwin Building Cambridge Science Park, Milton Road, Cambridge Canbridgeshire CB4 OWG (GB). BARLAAM, Bernard, Christophe; As- traZeneca, Darwin Building Cambridge Science Park, Mil- ton Road, Cambridge Cambridgeshire CB4 OWG (GB). YANG, Bin; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US). (74) Agent: COOK, Andrew, James; AstraZeneca Milstein Building, Cambridge Cambridgeshire CB21 6GH (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) Published: — with international search report (Art. 21(3)) (54) Title: ESTROGEN RECEPTOR MODULATORS R 1 \ D—E N/ \ Rio A , Q R9 \ R 20 R 17 N R, G 2 H R 18 R 3 / R R 7 (I) \" (57) : The specification relates to compounds of Formula (I): (I) Sand to pharmaceutically acceptable salts thereof, to processes ,„.,„ and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders. 18/ 138303 Al